Developer docs
API playgroundTry for free, no card

Search company profiles

Arisan Therapeutics

Full company profile

uuid0003zda

Namestring
Arisan Therapeutics
Websiteurl
arisanthera.com
Company typeenum
Private
Founded yearint
2010
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
infectious disease therapeutics, antiviral drug development, neglected disease treatments, ebola virus therapeutics, preclinical drug discovery
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arisan Therapeutics is a pre-commercial life science company developing novel therapeutic candidates for the treatment of neglected and emerging infectious diseases, with a primary focus on Ebola virus therapeutics. The company operates in the early-stage drug discovery and development phase, advancing antiviral candidates toward preclinical and clinical milestones.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Ebola Virus Therapeutics
CategoryAntiviral Drug Development
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Ridgeback Biotherapeutics
TypeDirect peer
Description

Clinical-stage biotech focused on Ebola therapeutics and other high-priority infectious diseases. Compares directly to Arisan in target indication, stage of development, and small-team biotech operating model.

2Mapp Biopharmaceutical
TypeDirect peer
Description

Small-cap biotech developer of monoclonal antibody therapeutics for Ebola (ZMapp, ZMapp-related cocktails). Direct peer to Arisan: comparable size, scope, and Ebola therapeutic focus, with similar dependence on government funding and stockpiling contracts.

3SIGA Technologies
TypeDirect peer
Description

Develops antiviral therapeutics for biodefense indications (e.g., Tpoxx for smallpox). Compares to Arisan as a small-cap biodefense antiviral company dependent on government stockpiling and BARDA-style procurement.

4BioCryst Pharmaceuticals
TypeDirect peer
Description

Develops small-molecule antivirals for rare and emerging infectious diseases. Comparable to Arisan in modality (small-molecule antivirals), therapeutic area (high-priority pathogens), and reliance on government stockpiling and orphan-disease commercial economics.

5Regeneron Pharmaceuticals
TypeBroad incumbent
Description

Developed Inmazeb/REGN-EB3, an FDA-approved therapeutic for Ebola Zaire. Comparable to Arisan in the Ebola therapeutics category, but Regeneron is a much larger, diversified biopharmaceutical incumbent that has already captured the regulatory and commercial frontier in this indication.

6Gilead Sciences
TypeBroad incumbent
Description

Developed remdesivir (Veklury), a broad antiviral with demonstrated activity against Ebola virus. Comparable to Arisan as a competitor in the Ebola therapeutic space, but Gilead is a large, diversified antiviral powerhouse with vastly greater resources.

7Emergent BioSolutions
TypeBroad incumbent
Description

Diversified biodefense and infectious disease company with both vaccine and therapeutic franchises. Comparable as a competitor in the broader biodefense landscape and as a potential strategic acquirer or licensing partner for Arisan's Ebola therapeutic.

8Bavarian Nordic
TypeBroad incumbent
Description

Develops vaccines and antivirals for infectious diseases, including an approved Ebola vaccine (Zabdeno/Mvabea regimen) and other biodefense franchises. Comparable to Arisan in Ebola-focused infectious disease development and small-to-mid cap biodefense positioning.

9Merck & Co.
TypeBroad incumbent
Description

Co-developed and commercialized Ervebo (V920), the first FDA-approved Ebola Zaire vaccine. Comparable to Arisan in the Ebola therapeutics/adjacent space, though Merck is a global pharmaceutical incumbent with a much broader pipeline and distribution footprint.

10Novavax
TypeEmerging player
Description

Emerging clinical-stage biotech with platform focus on recombinant nanoparticle vaccines and adjuvanted immunotherapies targeting infectious diseases. Comparable to Arisan in size, stage, infectious-disease focus, and reliance on government-funded infectious-disease contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arisan Therapeutics

Infectious Disease Therapeuticsarisanthera.com

Arisan Therapeutics firmographics

Firmographics
Name
Arisan Therapeutics
Website
https://arisanthera.com
Company type
Private
Founded year
2010
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Arisan Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Arisan Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Arisan Therapeutics product offering

Product offering

Core offering

Arisan Therapeutics is a pre-commercial life science company developing novel therapeutic candidates for the treatment of neglected and emerging infectious diseases, with a primary focus on Ebola virus therapeutics. The company operates in the early-stage drug discovery and development phase, advancing antiviral candidates toward preclinical and clinical milestones.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ebola Virus Therapeutics

Companies that use Arisan Therapeutics

Customer profile

Ideal customer profiles1 record

Arisan Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arisan Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Arisan Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ridgeback Biotherapeutics: Clinical-stage biotech focused on Ebola therapeutics and other high-priority infectious diseases. Compares directly to Arisan in target indication, stage of development, and small-team biotech operating model.
  • Mapp Biopharmaceutical: Small-cap biotech developer of monoclonal antibody therapeutics for Ebola (ZMapp, ZMapp-related cocktails). Direct peer to Arisan: comparable size, scope, and Ebola therapeutic focus, with similar dependence on government funding and stockpiling contracts.
  • SIGA Technologies: Develops antiviral therapeutics for biodefense indications (e.g., Tpoxx for smallpox). Compares to Arisan as a small-cap biodefense antiviral company dependent on government stockpiling and BARDA-style procurement.
  • BioCryst Pharmaceuticals: Develops small-molecule antivirals for rare and emerging infectious diseases. Comparable to Arisan in modality (small-molecule antivirals), therapeutic area (high-priority pathogens), and reliance on government stockpiling and orphan-disease commercial economics.

Broad incumbents

  • Regeneron Pharmaceuticals: Developed Inmazeb/REGN-EB3, an FDA-approved therapeutic for Ebola Zaire. Comparable to Arisan in the Ebola therapeutics category, but Regeneron is a much larger, diversified biopharmaceutical incumbent that has already captured the regulatory and commercial frontier in this indication.
  • Gilead Sciences: Developed remdesivir (Veklury), a broad antiviral with demonstrated activity against Ebola virus. Comparable to Arisan as a competitor in the Ebola therapeutic space, but Gilead is a large, diversified antiviral powerhouse with vastly greater resources.
  • Emergent BioSolutions: Diversified biodefense and infectious disease company with both vaccine and therapeutic franchises. Comparable as a competitor in the broader biodefense landscape and as a potential strategic acquirer or licensing partner for Arisan's Ebola therapeutic.
  • Bavarian Nordic: Develops vaccines and antivirals for infectious diseases, including an approved Ebola vaccine (Zabdeno/Mvabea regimen) and other biodefense franchises. Comparable to Arisan in Ebola-focused infectious disease development and small-to-mid cap biodefense positioning.
  • Merck & Co. Co-developed and commercialized Ervebo (V920), the first FDA-approved Ebola Zaire vaccine. Comparable to Arisan in the Ebola therapeutics/adjacent space, though Merck is a global pharmaceutical incumbent with a much broader pipeline and distribution footprint.

Emerging players

  • Novavax: Emerging clinical-stage biotech with platform focus on recombinant nanoparticle vaccines and adjuvanted immunotherapies targeting infectious diseases. Comparable to Arisan in size, stage, infectious-disease focus, and reliance on government-funded infectious-disease contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Arisan Therapeutics social profiles

Digital presence

Arisan Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arisan Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Arisan Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arisan Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arisan Therapeutics

What does Arisan Therapeutics do?

Arisan Therapeutics is a pre-commercial life science company developing novel therapeutic candidates for the treatment of neglected and emerging infectious diseases, with a primary focus on Ebola virus therapeutics. The company operates in the early-stage drug discovery and development phase, advancing antiviral candidates toward preclinical and clinical milestones.

When was Arisan Therapeutics founded?

Arisan Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is Arisan Therapeutics based?

Arisan Therapeutics is headquartered in San Diego, United States, in the North America region.

Who are Arisan Therapeutics's main competitors?

Direct peers on record are Ridgeback Biotherapeutics, Mapp Biopharmaceutical, SIGA Technologies and BioCryst Pharmaceuticals. Broad incumbents are Regeneron Pharmaceuticals, Gilead Sciences, Emergent BioSolutions, Bavarian Nordic and Merck & Co.. Novavax is listed as an emerging player.

Does Arisan Therapeutics have an API?

No public API is recorded for Arisan Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceArisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus InfectionNIAID awarded Arisan Therapeutics a contract to develop its lead small-molecule antiviral for Ebola virus disease, with an initial $3 million and up to $24 million total. The compound showed preclinical activity against three filoviruses and post-exposure efficacy in a mouse model. The project includes IND-enabling studies and Phase 1 development.FinancialContent Business PageArisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus InfectionArisan Therapeutics has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) to develop a small-molecule antiviral candidate for treating filovirus infections such as Ebola. The initial award is valued at $3 million, with potential total funding reaching $24 million if all milestones are met over an 11-month base period plus option periods. This funding will support IND-enabling studies and Phase 1 clinical development for the orally administered therapeutic.PR NewswireLamdaGen and Arisan Therapeutics Receive a $2 Million NIH SBIR Phase II Grant to Develop a Dual Rapid Point-of-Care Test for Acute Dengue and Zika Viral InfectionsLamdaGen Corporation and Arisan Therapeutics have been awarded a $2 million Phase II SBIR grant from the National Institutes of Health to develop a dual point-of-care diagnostic test for acute dengue and Zika viral infections. The collaboration will integrate Arisan's specific antibodies into LamdaGen's L'AuRa digital diagnostic platform to create a rapid, high-sensitivity assay capable of differentiating between the two viruses.